{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:09:50Z","timestamp":1771949390961,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006512","name":"Duke University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006512","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jacc.2025.11.034","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:07:15Z","timestamp":1767798435000},"page":"785-787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Some Much-Needed CONFIDENCE to Combat the Risk-Treatment Paradox in Chronic Kidney Disease"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2589-6993","authenticated-orcid":false,"given":"Daniel","family":"Edmonston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.11.034_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.034_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.034_bib3","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.0000000000000248","article-title":"Effect of SGLT2 inhibitors on discontinuation of renin-angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials","volume":"34","author":"Fletcher","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.11.034_bib4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2025.0686","article-title":"SGLT2 inhibitors and risk for hyperkalemia among individuals receiving RAAS inhibitors","volume":"185","author":"Wing","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.jacc.2025.11.034_bib5","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2025.10.049","article-title":"Risk of hyperkalemia with empagliflozin, finerenone, or both: secondary analysis of the CONFIDENCE randomized trial","volume":"87","author":"Agarwal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.034_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2215\/CJN.0000000000000300","article-title":"SGLT2 Inhibition and kidney potassium homeostasis","volume":"19","author":"Palmer","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.11.034_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.18808","article-title":"Concordance with screening and treatment guidelines for chronic kidney disease in type 2 diabetes","volume":"7","author":"Edmonston","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.034_bib8","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.mayocp.2022.07.010","article-title":"Submaximal angiotensin-converting enzyme inhibitor and angiotensin receptor blocker dosing among persons with proteinuria","volume":"97","author":"Chu","year":"2022","journal-title":"Mayo Clin Proc"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725103392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725103392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:48:26Z","timestamp":1771948106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725103392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0735109725103392"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.11.034","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Some Much-Needed CONFIDENCE to Combat the Risk-Treatment Paradox in Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.11.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.10.049","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}